Cliavist in Infectious and Degenerative Diseases of the Spine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by University Hospital, Strasbourg, France.
Recruitment status was:  Recruiting
Information provided by:
University Hospital, Strasbourg, France Identifier:
First received: September 4, 2006
Last updated: February 24, 2009
Last verified: February 2009
USPIO contrast enhancement results from intracellular trapping of the iron particles in reactive cells, especially macrophages. 17FDG-PET studies have demonstrated that macrophages are present in spine infectious diseases but are absent in spine degenerative diseases. The aim of this work is to compare the enhancement induced by CLIAVIST in both diseases. The absence of macrophages in degenerative lesions should help to differentiate them from infectious lesions, who should present contrast enhancement in relation to the presence of macrophages.

Condition Intervention Phase
Spine Infection
Drug: Cliavist
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Comparison of Cliavist Enhancement in Infectious and Degenerative Diseases of the Spine

Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:
  • First MRI: performed immediately after gadolinium administration [ Time Frame: immediately after gadolinium administration ]
  • Second MRI: performed 24 hours after cliavist administration [ Time Frame: 24 hours after cliavist administration ]

Estimated Enrollment: 40
Study Start Date: March 2007
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cliavist Drug: Cliavist
Injection of 0,9 mL (weight < 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • spine infection or spine degenerative disease
  • patient agreement obtained

Exclusion Criteria:

  • pregnancy
  • MRI contra-indications
  • cliavist contra-indication
  • dextran allergy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00372281

Service de Neuroradiologie - Hôpital Central
Nancy, France, 54035
Nouvel Hôpital Civil
Strasbourg, France, 67091
Service de Radiologie 2 - Hôpital de Hautepierre
Strasbourg, France, 67098
Service de Rhumatologie - Hôpital de Hautepierre
Strasbourg, France, 67098
Sponsors and Collaborators
University Hospital, Strasbourg, France
Study Director: Jean-Louis Dietemann, MD Hôpitaux Universitaires de Strasbourg
  More Information

Responsible Party: Christine GEILLER, Direction de la Recherche Clinique et de l'Innovation - Hôpitaux Universitaires de Strasbourg Identifier: NCT00372281     History of Changes
Other Study ID Numbers: 3780 
Study First Received: September 4, 2006
Last Updated: February 24, 2009

Keywords provided by University Hospital, Strasbourg, France:
MRI, CLIAVIST, MACROPHAGE, INFECTION, SPINE processed this record on January 19, 2017